Crescent Biopharma Statistics
Total Valuation
CBIO has a market cap or net worth of $720.77 million. The enterprise value is $550.61 million.
| Market Cap | 720.77M |
| Enterprise Value | 550.61M |
Important Dates
The last earnings date was Thursday, July 30, 2026, before market open.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CBIO has 42.80 million shares outstanding.
| Current Share Class | 37.14M |
| Shares Outstanding | 42.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 4.79% |
| Owned by Institutions (%) | 51.96% |
| Float | 26.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 60.66 |
| Forward PS | 864.92 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 4.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 46.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.66 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -102.59% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $172,217 |
| Profits Per Employee | -$2.39M |
| Employee Count | 69 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CBIO has paid $2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +53.09% |
| 50-Day Moving Average | 17.06 |
| 200-Day Moving Average | 14.98 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 405,116 |
Short Selling Information
The latest short interest is 3.74 million, so 8.75% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short Previous Month | 3.67M |
| Short % of Shares Out | 8.75% |
| Short % of Float | 14.17% |
| Short Ratio (days to cover) | 8.37 |
Income Statement
In the last 12 months, CBIO had revenue of $11.88 million and -$165.12 million in losses. Loss per share was -$6.03.
| Revenue | 11.88M |
| Gross Profit | 11.88M |
| Operating Income | -170.24M |
| Pretax Income | -163.12M |
| Net Income | -165.12M |
| EBITDA | -168.26M |
| EBIT | -168.47M |
| Loss Per Share | -$6.03 |
Balance Sheet
The company has $171.59 million in cash and $1.44 million in debt, with a net cash position of $170.16 million or $3.98 per share.
| Cash & Cash Equivalents | 171.59M |
| Total Debt | 1.44M |
| Net Cash | 170.16M |
| Net Cash Per Share | $3.98 |
| Equity (Book Value) | 163.26M |
| Book Value Per Share | 4.77 |
| Working Capital | 160.47M |
Cash Flow
In the last 12 months, operating cash flow was -$72.68 million and capital expenditures -$939,000, giving a free cash flow of -$73.62 million.
| Operating Cash Flow | -72.68M |
| Capital Expenditures | -939,000 |
| Depreciation & Amortization | 212,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -73.62M |
| FCF Per Share | -$1.72 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,432.63% |
| Pretax Margin | -1,372.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -22.91% |
| FCF Yield | -10.21% |
Analyst Forecast
The average price target for CBIO is $30.60, which is 81.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.60 |
| Price Target Difference | 81.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -8.90% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CBIO has an Altman Z-Score of 7.44 and a Piotroski F-Score of 1.
| Altman Z-Score | 7.44 |
| Piotroski F-Score | 1 |